Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - Pharmaceutical News - Researchers from Ghent University Hospital Report on Findings in Asthma (Stratification of eosinophilic asthma patients treated with reslizumab and... - September 19, 2017

Pharmacy News Article

 9/13/17 - Researchers from Ghent University Hospital Report on Findings in Asthma (Stratification of eosinophilic asthma patients treated with reslizumab and...

Researchers from Ghent University Hospital Report on Findings in Asthma (Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy)

By a News Reporter-Staff News Editor at Immunotherapy Weekly Researchers detail new data in Lung Diseases and Conditions - Asthma. According to news originating from Ghent, Belgium, by NewsRx correspondents, research stated, "Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies. This secondary analysis assessed reslizumab's efficacy in patients receiving baseline treatment per Global Initiative for Asthma (GINA) Step 4 and Step 5 guidelines."

Our news journalists obtained a quote from the research from Ghent University Hospital, "Pooled data from duplicate, Phase III, reslizumab placebo studies in patients with severe eosinophilic asthma (blood eosinophils greater than or equal to400 cellsL) were stratified by baseline therapy. Efficacy assessments were exacerbation rates and changes from baseline forced expiratory volume in 1 s (FEV) and patient-reported outcomes. Of 953 patients, 69% (n=657) and 11% (n=106) were receiving Step 4 and Step 5 therapy, respectively. Compared with placebo, reslizumab reduced exacerbation rates by 53% (95% CI 0.36-0.62) and 72% (95% CI 0.15-0.52), in Step 4 and Step 5 groups respectively. By study end, reslizumab increased FEV in Step 4 and Step 5 groups by 103 mL (95% CI 52-154 mL) and 237 mL (95% CI 68-407 mL), respectively. Reslizumab also improved patient-reported outcomes compared with placebo in both groups."

According to the news editors, the research concluded: "Reslizumab reduces exacerbation rates and improves lung function and patient-reported outcomes in patients with eosinophilic asthma receiving therapy per Steps 4 and 5 of the GINA guidelines."

For more information on this research see: Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy. Erj Open Research, 2017;3(3): (see also Lung Diseases and Conditions - Asthma).

The news correspondents report that additional information may be obtained from G. Brusselle, Dept. of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. Additional authors for this research include J. Canvin, S. Weiss, S.X. Sun and R. Buhl.

Keywords for this news article include: Ghent, Europe, Asthma, Belgium, Therapy, Respiratory Hypersensitivity, Bronchial Diseases and Conditions, Immune System Diseases and Conditions, Obstructive Lung Diseases and Conditions, Respiratory Tract Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Sep 19: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Last Chance
Sep 20: What's New? New Treatments for Type 2 Diabetes
Sep 21: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Sep 22: Influenza 2017-2018: An Update on Prevention and Treatment
Sep 24: Using Effective Communication to Reduce Medication Errors
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415